Experimental combo for lung cancer shows early promise but trial halted
NCT ID NCT05141357
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This phase 2 trial tested a combination of two drugs—HBI-8000 (tucidinostat) and pembrolizumab (Keytruda)—in adults with advanced or metastatic non-small cell lung cancer whose tumors have a specific marker (PD-L1 ≥1%). Only 5 people took part, and the study was stopped early. The main goal was to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CBCC Global Research, Inc at Comprehensive Blood and Cancer Center
Bakersfield, California, 93309, United States
-
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606, United States
-
Frederick Health-JMSCI
Frederick, Maryland, 21702, United States
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Midewestern Regional Medical Center, LLC
Zion, Illinois, 60099, United States
-
Southeastern Regional Medical Center
Newnan, Georgia, 30265, United States
-
Western Regional Medical Center
Goodyear, Arizona, 85338, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBI-8000 (tucidinostat) combined with pembrolizumab (Keytruda)
What this could lead to
If successful, this combination could offer a new treatment option for advanced lung cancer patients who have not had immunotherapy before.
What could go wrong
This was a very small, early-phase trial (only 5 participants) that was terminated early, so results are limited. The combination may not prove safe or effective in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.